Molecular Partners AG (MOLN)
3.87
+0.16
(+4.31%)
USD |
NASDAQ |
May 16, 16:00
Molecular Partners Free Cash Flow: -66.61M for Dec. 31, 2023
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| December 31, 2023 | -66.61M |
| September 30, 2023 | -63.16M |
| June 30, 2023 | -66.63M |
| March 31, 2023 | -71.87M |
| December 31, 2022 | 122.83M |
| Date | Value |
|---|---|
| September 30, 2022 | 114.79M |
| June 30, 2022 | 113.19M |
| March 31, 2022 | 108.94M |
| December 31, 2021 | -100.94M |
Free Cash Flow Range, Past 5 Years
-100.94M
Minimum
Dec 2021
122.83M
Maximum
Dec 2022
10.06M
Average
-63.16M
Median
Sep 2023
Free Cash Flow Benchmarks
| AC Immune SA | -48.92M |
| CRISPR Therapeutics AG | -169.05M |
| Addex Therapeutics Ltd | -8.908M |
| NLS Pharmaceutics Ltd | -- |
| MoonLake Immunotherapeutics | -48.91M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -17.00M |
| Cash from Investing (Quarterly) | 21.20M |
| Cash from Financing (Quarterly) | -0.3157M |
| Free Cash Flow Per Share (Quarterly) | -0.5277 |
| Free Cash Flow to Equity (Quarterly) | -17.34M |
| Free Cash Flow to Firm (Quarterly) | -17.34M |
| Free Cash Flow Yield | -52.52% |